FOXP3 and primary cutaneous T-cell non-Hodgkin lymphoma: LNs (46) This is likely due to different cell-killing mechanisms in these two types of depletion agents; immunotoxins kill a cell through the inhibition of protein synthesis (76), whereas antibodies require an environmental support, e.g. neutrophils, to deplete T cells (35, 102).Previous Alemtuzumab therapy for CTCL patients showed inefficient depletion of skin-resident T cells, including Foxp3+ regulatory T cells (35, 109), whereas CD3-IT [A-dmDT (390)-bisFv(UCHT1)] showed effective depletion of skin-resident T cells in human foreskin-grafted humanized mice (35).